Trial · NCT05022563
Results by group750
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 750
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Interruption in Index Anticoagulant Treatment | Warfarin-Based Therapy | Without Active Cancer | 3429 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy | Without Active Cancer | 8169 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Apixaban | Without Active Cancer | 965 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Dabigatran | Without Active Cancer | 492 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Edoxaban | Without Active Cancer | 439 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Rivaroxaban | Without Active Cancer | 5973 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | PAC Only | Without Active Cancer | 1226 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | Warfarin-Based Therapy | With Active Cancer | 172 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy | With Active Cancer | 961 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Apixaban | With Active Cancer | 115 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Dabigatran | With Active Cancer | 51 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Edoxaban | With Active Cancer | 38 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | NOAC-Based Therapy: Rivaroxaban | With Active Cancer | 728 | Participants | |
| Number of Participants With Interruption in Index Anticoagulant Treatment | PAC Only | With Active Cancer | 401 | Participants | |
| Time to Treatment Interruption | Warfarin-Based Therapy | Without Active Cancer | 163 | Inter-Quartile Range 50 to 343 | Days |
| Time to Treatment Interruption | NOAC-Based Therapy | Without Active Cancer | 129 | Inter-Quartile Range 37 to 189 | Days |
| Time to Treatment Interruption | NOAC-Based Therapy: Apixaban | Without Active Cancer | 86 | Inter-Quartile Range 16 to 181 | Days |
| Time to Treatment Interruption | NOAC-Based Therapy: Dabigatran | Without Active Cancer | 137 | Inter-Quartile Range 56 to 188 | Days |
| Time to Treatment Interruption | NOAC-Based Therapy: Edoxaban | Without Active Cancer | 130 | Inter-Quartile Range 42 to 189 | Days |
| Time to Treatment Interruption | NOAC-Based Therapy: Rivaroxaban | Without Active Cancer | 128 | Inter-Quartile Range 38 to 188 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05022563/results